TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

Glo-BNHL international clinical site monitoring

Research and development services and related consultancy services
West Midlands (UKG31)
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: THE UNIVERSITY OF BIRMINGHAM: "Glo-BNHL international clinical site monitoring". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityTHE UNIVERSITY OF BIRMINGHAMScope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: THE UNIVERSITY OF BIRMINGHAM
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for THE UNIVERSITY OF BIRMINGHAM. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
3.4Bids / Report
48.4% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 152 active published awards; 31 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityTHE UNIVERSITY OF BIRMINGHAM
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSNot published
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published9 Jan 2024, 15:08 GMT
Last source update9 Jan 2024, 15:08 GMT
Recurring procurementNot published
ClassificationResearch and development services and related consultancy services
Delivery area
West Midlands (UKG31)
OCIDocds-h6vhtk-042bb3
What is being bought
Glo-BNHL is an international multi-arm clinical trial developed in collaboration with a number of key childhood cancer research organisations, including Innovative Therapies for Children with Cancer (ITCC) and the European Intergroup for Childhood NHL (EICNHL) in Europe, and the Children's Oncology Group (COG) in North America. The trial will be delivered globally with support from these organisations and in partnership with the C17 Council in Canada and the Australia and New Zealand Children's Haematology and Oncology Group (ANZCHOG). The trial is jointly funded by Cancer Research UK, Fight Kids Cancer and industry collaborators (currently ADC Therapeutics and Regeneron Pharmaceuticals). The funding provided is contingent upon the use of vendors with a track record of delivering clinical trials of this kind. The Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham is not able to perform monitoring on an international scale, therefore a suitable third-party vendor must be engaged for this critical work.
What changed
From the official release history
  1. Status changed to complete
    9 Jan 2024, 15:08 GMT
  2. Official notice release published
    9 Jan 2024, 15:08 GMT
  3. Buyer information updated
    9 Jan 2024, 15:08 GMT
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    Status not published
    Published valueNot published
    Glo-BNHL is an international multi-arm clinical trial developed in collaboration with a number of key childhood cancer research organisations, including Innovative Therapies for Children with Cancer (ITCC) and the European Intergroup for Childhood NHL (EICNHL) in Europe, and the Children's Oncology Group (COG) in North America. The trial will be delivered globally with support from these organisations and in partnership with the C17 Council in Canada and the Australia and New Zealand Children's Haematology and Oncology Group (ANZCHOG). The trial is jointly funded by Cancer Research UK, Fight Kids Cancer and industry collaborators (currently ADC Therapeutics and Regeneron Pharmaceuticals). The funding provided is contingent upon the use of vendors with a track record of delivering clinical trials of this kind. The Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham is not able to perform monitoring on an international scale, therefore a suitable third-party vendor must be engaged for this critical work. The preferred vendor for clinical site monitoring is Premier Research. Premier were selected in 2020 to work on the Far-RMS trial after going to tender because they most closely fulfilled our needs as detailed below:  They are familiar with working with academic institutions of our kind, with over 85% of their client base being emerging sponsors and academic institutes  They have extensive experience in haemato-oncology projects operating globally (194 projects to date)  They have experience in the paediatric arena (261 studies over the past 5 years, 17 of those global, haemato-oncology studies)  They have a specialised paediatric training programme to ensure staff understand the unique challenges of paediatric research  They have expertise in global monitoring, having conducted studies in 75 countries worldwide and having 21 offices worldwide
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    9 Jan 2024, 15:08 GMT
  2. Award active
    Not published · Not published
  3. Contract active
    Signed 9 Jan 2024, 00:00 GMT · £0
Commercial outcome and competition
Awards
Premier Research Group Limited
Not published · Not published · active
Contracts
Contract
£0 · signed 9 Jan 2024, 00:00 GMT · active
Bid statisticsNo aggregate bid statistics published
Buyer and organisations in this procedure

THE UNIVERSITY OF BIRMINGHAM

Contracting authority GB-COH-RC000645
View buyer profile

  • THE UNIVERSITY OF BIRMINGHAM
    buyer

    GB-COH: RC000645
    Edgbaston, BIRMINGHAM, UKG31, B152TT
    K.Samsonik@bham.ac.uk

  • Premier Research Group Limited
    supplier

    GB-COH: 04671020
    Reading, UKJ11

  • University Of Birmingham
    reviewBody

    Edgbaston
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published
Planning and rationale
Planning budgetNot published
No-engagement rationaleNot published
Procedure rationaleThe preferred vendor for clinical site monitoring is Premier Research.  They are familiar with working with academic institutions of our kind, with over 85% of their client base being emerging sponsors and academic institutes  They have extensive experience in haemato-oncology projects operating globally (194 projects to date)  They have experience in the paediatric arena (261 studies over the past 5 years, 17 of those global, haemato-oncology studies)  They have a specialised paediatric training programme to ensure staff understand the unique challenges of paediatric research  They have expertise in global monitoring, having conducted studies in 75 countries worldwide and having 21 offices worldwide When deciding upon a partner to work with us on Glo-BNHL, we felt the expertise detailed above, as well as the following other considerations, made Premier the right choice for this trial::  Proven expertise in oncology trials, particularly rare disease trials  Proven expertise in paediatric trials  Proven expertise in global trials  Ability to perform interim and follow-up site monitoring visits (and proven experience of doing so) in the following countries: UK, Europe (Austria, Belgium, France, Germany, Italy, Netherlands, NOPHO (Sweden, Norway, Denmark, Finland), Poland, Spain), USA, Canada, Australia, New Zealand and Israel  Ability to perform interim and follow-up site monitoring visits across 45 sites  Ability to support the volume of data that will be produced by 30 patients per treatment arm according to the treatment schedule outlined in the Glo-BNHL protocol  Ability to work with the procedures and systems of the CRCTU at the University of Birmingham  Ability to develop a monitoring plan in conjunction with the Glo-BNHL trial management team